We are live on ! Find out more
RPAM

Rhenman & Partners Asset Management Portfolio holdings

AUM $810M
1-Year Est. Return 30.2%
This Fund
S&P 500
This Quarter Est. Return
+34.16%
1 Year Est. Return
+30.2%
3 Year Est. Return
+116.38%
5 Year Est. Return
+153.13%
10 Year Est. Return
+962.25%
AUM
$913M
AUM Growth
+$115M
Cap. Flow
-$67.2M
Cap. Flow %
-7.37%
Top 10 Hldgs %
28.56%
Holding
108
New
15
Increased
30
Reduced
36
Closed
14

Top Buys

Rank Stock Value
1
GH icon
Guardant Health
GH
+$8.67M
2
AXNX
Axonics, Inc. Common Stock
AXNX
+$7.88M
3
ISRG icon
Intuitive Surgical
ISRG
+$6.74M
4
BHVN
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
+$6.19M
5
LIVN icon
LivaNova
LIVN
+$6.07M

Top Sells

Rank Stock Value
1
CVS icon
CVS Health
CVS
+$11.5M
2
ALXN
Alexion Pharmaceuticals
ALXN
+$11.3M
3
TMO icon
Thermo Fisher Scientific
TMO
+$11.1M
4
COR icon
Cencora
COR
+$8.15M
5
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$7.67M

Sector Composition

Rank Sector Weight
1 Healthcare 93.54%
2 Financials 0.09%
3 Energy 0.09%
4 Technology 0.09%
5 Communication Services 0.06%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MDT icon
26
Medtronic
MDT
$112B
$14.2M 1.55%
125,030
-60,188
-32% -$6.6M
SGEN
27
DELISTED
Seagen Inc. Common Stock
SGEN
$13.7M 1.5%
120,000
-28,700
-19% -$3.04M
IOVA icon
28
Iovance Biotherapeutics
IOVA
$2.87B
$13.1M 1.44%
475,000
-45,000
-9% -$1.02M
NBIX icon
29
Neurocrine Biosciences
NBIX
$16.6B
$12.9M 1.41%
120,000
-29,600
-20% -$3.1M
GKOS icon
30
Glaukos
GKOS
$10.6B
$12.8M 1.4%
235,000
+5,400
+2% +$329K
GH icon
31
Guardant Health
GH
$22.6B
$12.1M 1.33%
155,268
+120,268
+344% +$8.67M
DERM
32
DELISTED
Dermira, Inc.
DERM
$12.1M 1.33%
800,000
+250,700
+46% +$2.16M
KYNB
33
Kyntra Bio
KYNB
$29.4M
$11.8M 1.29%
11,000
-800
-7% -$817K
MGNX icon
34
MacroGenics
MGNX
$257M
$11.5M 1.26%
1,060,000
+260,627
+33% +$2.58M
XNCR icon
35
Xencor
XNCR
$1.55B
$10.7M 1.17%
310,000
+7,477
+2% +$273K
EPZM
36
DELISTED
Epizyme, Inc
EPZM
$10.5M 1.15%
425,000
-25,028
-6% -$372K
CVS icon
37
CVS Health
CVS
$122B
$10.4M 1.14%
140,214
-163,554
-54% -$11.5M
HCA icon
38
HCA Healthcare
HCA
$89.5B
$10.3M 1.13%
70,000
-5,000
-7% -$671K
REGN icon
39
Regeneron Pharmaceuticals
REGN
$80.8B
$10.1M 1.11%
27,000
-18,031
-40% -$6.07M
ARNA
40
DELISTED
Arena Pharmaceuticals Inc
ARNA
$9.99M 1.1%
220,000
+65,000
+42% +$3.07M
EXAS
41
DELISTED
Exact Sciences
EXAS
$9.89M 1.08%
107,000
-786
-0.7% -$69.1K
BDX icon
42
Becton Dickinson
BDX
$48.2B
$9.25M 1.01%
34,850
-29,725
-46% -$7.41M
AXNX
43
DELISTED
Axonics, Inc. Common Stock
AXNX
$9.14M 1%
+330,000
New +$7.88M
EW icon
44
Edwards Lifesciences
EW
$51.7B
$8.87M 0.97%
114,000
+4,245
+4% +$331K
CNC icon
45
Centene
CNC
$32.5B
$8.8M 0.96%
140,000
-35,000
-20% -$1.9M
AMRN
46
Amarin Corp
AMRN
$303M
$8.58M 0.94%
20,000
– –
SILK
47
DELISTED
Silk Road Medical, Inc. Common Stock
SILK
$8.46M 0.93%
209,381
+84,381
+68% +$2.95M
STML
48
DELISTED
Stemline Therapeutics, Inc.
STML
$8.08M 0.89%
760,181
+249,158
+49% +$2.47M
OMCL icon
49
Omnicell
OMCL
$1.68B
$7.76M 0.85%
95,000
+5,000
+6% +$384K
AGIO icon
50
Agios Pharmaceuticals
AGIO
$1.93B
$7.64M 0.84%
160,000
-85,002
-35% -$3.21M
1
2
3 4 5

Similar funds

PS
Portfolio Strategies Monsey, New York $811M AUM 28.91% 1-Year Est. Return
ACM
Ashford Capital Management Wilmington, Delaware $809M AUM 35.1% 1-Year Est. Return
AR
Advisory Research Chicago, Illinois $813M AUM 36.71% 1-Year Est. Return
KCP
Kera Capital Partners San Jose, California $815M AUM 46.39% 1-Year Est. Return
BCM
Brigade Capital Management New York $806M AUM 20.71% 1-Year Est. Return
RIM
Redwood Investment Management Scottsdale, Arizona $805M AUM 15.01% 1-Year Est. Return
GCM
Glendon Capital Management Santa Monica, California $805M AUM 17.91% 1-Year Est. Return
CL
CVFG LLC Shelbyville, Indiana $804M AUM 27.61% 1-Year Est. Return

Rhenman & Partners Asset Management's Q4 2019 Portfolio in Review

As of Q4 2019, Rhenman & Partners Asset Management held 108 positions worth $913M, up 14% from $798M the previous quarter. Its ten largest holdings account for 29% of the portfolio.

Rhenman & Partners Asset Management withdrew a net $67.2M in Q4 2019, closing 14 positions and reducing 36 holdings. Its most notable exit was Thermo Fisher Scientific, an estimated $11.1M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 94% of assets, up from 93% a quarter earlier, followed by Financials and Energy.

Against the trend, Rhenman & Partners Asset Management opened a new position in Axonics, Inc. Common Stock worth $9.14M.

  • Rhenman & Partners Asset Management's largest Q4 2019 buy was Axonics, Inc. Common Stock: 330,000 shares worth $9.14M.
  • Rhenman & Partners Asset Management added most to Guardant Health in Q4 2019, an estimated $8.67M increase.
  • Rhenman & Partners Asset Management's biggest Q4 2019 reduction was CVS Health, cutting an estimated $11.5M.
  • Rhenman & Partners Asset Management fully exited Thermo Fisher Scientific in Q4 2019, selling an estimated $11.1M.
  • Rhenman & Partners Asset Management's ten largest holdings make up 29% of its $913M portfolio in Q4 2019.
  • Rhenman & Partners Asset Management opened 15 new positions and closed 14 in Q4 2019.
  • Rhenman & Partners Asset Management's portfolio value rose 14% quarter-over-quarter to $913M.

Based on Rhenman & Partners Asset Management's 13F filing for Q4 2019, filed 17 Jan 2020.